Back to top
more

Antares Pharma, Inc. (ATRS)

(Delayed Data from NSDQ)

$3.04 USD

3.04
1,289,259

+0.06 (2.01%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.04 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ATRS]

Reports for Purchase

Showing records 1 - 20 ( 49 total )

Industry: Medical - Dental Supplies

Record: 1

04/14/2022

Company Report

Pages: 7

Takeout by Drug-Delivery Player Halozyme; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 2

03/07/2022

Company Report

Pages: 8

4Q21 and 2022 Guidance Ahead of Estimates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 3

02/24/2022

Company Report

Pages: 7

Model Update Ahead of 2022 First-Time Guidance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 4

01/10/2022

Company Report

Pages: 6

Buisness Updates for 2022

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 5

11/05/2021

Company Report

Pages: 9

Gx Forteo Delay and Increased Spend Brings Nerves about 2022; Tlando is Accretive, But Risk Discount Lowers Our PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 6

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ATRS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 7

08/06/2021

Company Report

Pages: 9

2Q21: Solid Beat Despite One-time Drags, Sets Up Strong 2H; Looking for Gx Forteo and AR-1902 Clarity

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 8

05/10/2021

Company Report

Pages: 9

1Q21: EpiPen Blowing the Doors Off; Raise Gx Forteo Royalties and Target to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 9

11/16/2020

Company Report

Pages: 8

3Q20: Xyosted and EpiPen Continue to Drive Ship; Street Nocdurna Expectations are Low; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 10

11/16/2020

Company Report

Pages: 6

Multiple Sclerosis Therapy Demonstrates Early Signs of Durability

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 11

10/02/2020

Company Report

Pages: 6

Small Nocdurna Tuck-in Acquisition to Leverage the Successful Xyosted Salesforce; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 12

08/10/2020

Company Report

Pages: 7

2Q20: Steady Grower Xyosted Drives Another Beat; Pre-COVID Guidance Reinstated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 13

05/06/2020

Company Report

Pages: 9

1Q20: Guidance Withdrawn on COVID

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 14

04/02/2020

Company Report

Pages: 5

Atara Reports On COVID-19 Impact

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 15

03/04/2020

Company Report

Pages: 10

4Q19: Continuing the Hot Beat Streak; 2020 Set for First Full-Year Profitability; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 16

01/24/2020

Company Report

Pages: 8

Adjusting Numbers Following Partner Updates; Lower 2020 Royalties, But Long-Term Growth Unchanged; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 17

11/06/2019

Company Report

Pages: 11

3Q19 Results: Another Beat and Revenue Guidance Bump; First Ever Profit, Raise Target to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 18

08/07/2019

Company Report

Pages: 8

2Q19: Another Solid Beat, Including Xyosted; We Still See 4Q Breakeven; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 19

05/06/2019

Company Report

Pages: 8

1Q19 Results; Strength Across the Portfolio; Xyosted Solid Rx out of the Gates; Still See 4Q Breakeven

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Dental Supplies

Record: 20

03/11/2019

Company Report

Pages: 8

Makena Anxiety Likely Overblown; Updating Estimates Post 4Q18; We See a Back-Weighted 2019; Breakeven in 4Q19

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party
// eof